We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Cognitive Effects of Atomoxetine in Humans: Genetic Moderators

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01498549
Recruitment Status : Completed
First Posted : December 23, 2011
Results First Posted : June 8, 2017
Last Update Posted : July 11, 2017
Information provided by (Responsible Party):

Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Crossover Assignment;   Masking: Double (Participant, Investigator);   Primary Purpose: Treatment
Condition: Addiction
Interventions: Drug: Atomoxetine
Drug: Sugar Pill

  Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
Participants Participants were randomly assigned to one of 3 possible groups over a 3 day assessment period.

Participant Flow:   Overall Study
Atomoxetine 40 mg   39 
Atomoxetine 80 mg   37 
Sugar Pill 0 mg   36 
COMPLETED [1]   35 
[1] Completed all 3 days for each arm in the crossover design.

  Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
The total number of people enrolled in the study before randomization to crossover assignment.

Reporting Groups
Total Sample This is the summary of the total sample used in the crossover design.

Baseline Measures
   Total Sample 
Overall Participants Analyzed 
[Units: Participants]
[Units: Years]
Mean (Standard Deviation)
 41.21  (7.47) 
Sex: Female, Male 
[Units: Participants]
Count of Participants
Female      10  25.6% 
Male      29  74.4% 
Ethnicity (NIH/OMB) 
[Units: Participants]
Count of Participants
Hispanic or Latino      3   7.7% 
Not Hispanic or Latino      36  92.3% 
Unknown or Not Reported      0   0.0% 
Race (NIH/OMB) 
[Units: Participants]
Count of Participants
American Indian or Alaska Native      0   0.0% 
Asian      0   0.0% 
Native Hawaiian or Other Pacific Islander      0   0.0% 
Black or African American      21  53.8% 
White      18  46.2% 
More than one race      0   0.0% 
Unknown or Not Reported      0   0.0% 

  Outcome Measures

1.  Primary:   Rapid Visual Information Processing   [ Time Frame: 2 years ]

2.  Primary:   Rapid Visual Information Processing: Mean Correct Response Latency   [ Time Frame: 2 years ]

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

  More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.

Results Point of Contact:  
Name/Title: Dr. Mehmet Sofuoglu, Professor of Psychiatry; Director of VA New England Mental Illness Research, Ed
Organization: Yale University
phone: (203) 937-4809
e-mail: mehmet.sofuoglu@yale.edu

Responsible Party: Mehmet Sofuoglu, Yale University
ClinicalTrials.gov Identifier: NCT01498549     History of Changes
Other Study ID Numbers: 1103008235
First Submitted: December 20, 2011
First Posted: December 23, 2011
Results First Submitted: February 8, 2017
Results First Posted: June 8, 2017
Last Update Posted: July 11, 2017